A National Cancer Institute workshop found conclusive evidence that cannabinoids help chemotherapy-induced nausea and suggestive evidence for cancer pain, while highlighting underappreciated risks including infections, drug interactions, and vaping-related illness.
Cancer patients considering cannabis, oncologists, cancer researchers, healthcare policy professionals
Conclusive evidence for chemotherapy-induced nausea, suggestive evidence for cancer pain
What the researchers found
Conclusive evidence supports cannabinoids for chemotherapy-induced nausea and vomiting, with suggestive evidence for cancer-related pain. Risks for cancer patients include infection (immunocompromised), pharmacokinetic drug-botanical interactions, cannabinoid hyperemesis syndrome, and vaping-related lung injury.
Why it matters
Cancer patients are using cannabis at increasing rates while oncologists feel ill-equipped to advise them. The gap between patient demand and clinical guidance creates real risks, especially for immunocompromised patients.
The numbers in context
Cannabis remains Schedule I federally; conclusive evidence for chemo nausea; suggestive evidence for cancer pain; risks include infection, drug interactions, hyperemesis, vaping injury
How the study worked
Summary of Session 2 from the National Cancer Institute Cannabis, Cannabinoids, and Cancer Research Workshop, including patient testimony, legal landscape review, and evidence synthesis.
What this study cannot tell us
Workshop summary rather than systematic review. Evidence synthesis is necessarily broad rather than detailed. Legal barriers continue to limit research quality and quantity.
How to read the evidence
NCI expert workshop summary synthesizing available evidence across cancer-related cannabinoid research
When this study was published
Published in 2021. The conflict between federal scheduling and state medical cannabis laws continues to hamper research.
The bigger picture
The NCI workshop highlights a paradox: cannabis has legitimate uses in cancer care but the Schedule I classification makes it nearly impossible to conduct the research needed to guide its use safely.
Questions still open
- How can oncologists be better trained to counsel patients about cannabis? Would rescheduling cannabis accelerate the research needed for evidence-based cancer care guidelines? Which drug-cannabis interactions pose the greatest risk for cancer patients?
Common questions
Can cannabis help cancer patients?
What are the risks of cannabis for cancer patients?
Read the original research
Cannabis and the Cancer Patient.
Journal of the National Cancer Institute. Monographs, 2021(58), 68-77
Citation
Braun, Ilana M; Abrams, Donald I; Blansky, Stacey E; Pergam, Steven A. (2021). Cannabis and the Cancer Patient.. Journal of the National Cancer Institute. Monographs, 2021(58), 68-77. https://doi.org/10.1093/jncimonographs/lgab012
Explore the wider topic
- CBD Oil Quality Guide: How to Avoid Snake Oil
- Anxiety After Quitting Weed: When to Consider Medication
- Cannabis for Chemotherapy Nausea: What the Evidence Actually Shows
- Cannabis for Chronic Pain: What the Research Actually Supports
- Cannabis and Epilepsy: The Epidiolex Story and What It Means
- Does CBD Actually Work for Anxiety? What the Evidence Shows
- Does CBD Help with Weed Withdrawal? What Studies Show
- CBD vs THC: The Differences That Actually Matter
- The Proven Medical Benefits of Cannabis: What Research Supports
- Quitting Weed Before Surgery
- Weed and Medications: What Changes When You Quit
- Quitting Weed During Pregnancy: What You Need to Know
- Quitting Weed While Pregnant: What You Need to Know
- Cannabis and Older Adults: Risks Seniors Should Know
- Cannabis and Breastfeeding: THC in Breast Milk